Annals of Pharmacotherapy · 2019 · 10 citations · 18 references
PharmacyCardiologyPharmacotherapyGeneral Internal MedicinePatient SafetyPharmaceutical CareHeart FailureHeart Failure PharmacotherapyMedication AccessMedication ManagementMedication Use EvaluationReadmission Analysis30-Day ReadmissionGuideline-based TherapyGuideline-directed Medical TherapyGuideline-directed TherapyHeart Failure ReadmissionsMultidisciplinary Heart Failure CareReadmission RatesThirty-day Readmission
Background: Heart failure (HF) is highly prevalent in the Veterans Affairs (VA) health care system and the leading cause of hospital discharges in the VA. Despite guideline-specific recommendations of drug therapy, many patients are not on optimal medication regimens. Objective: To examine and quantify pharmacist impact in an interdisciplinary HF consult (IC) service on increasing use of guideline-directed medical therapy (GDMT). The 30-day readmission rates before and after the implementation of an IC service are reported. Methods: This was a single-center retrospective analysis of veterans admitted with a HF diagnosis between August 2008 and August 2015 in 2 distinctive cohorts: pre-IC (August 2008 to November 2011) and IC (November 2011 to August 2015). Results: Four-hundred patients were included, with 200 in each cohort. All-cause readmissions at 30 days were not different between pre-IC and IC groups: 33.5% versus 28.5%, respectively. Secondary outcomes of HF readmission and 1-year mortality were not different between groups. Significant increases in medication use rates were observed from admission to discharge in both cohorts; however, greater increases were observed in the IC group in which the pharmacist role was clearly defined in recommending GDMT optimization, especially in patients with HF with reduced ejection fraction. Conclusion and Relevance: Although the implementation of an IC service did not significantly change 30-day readmission rates, increases in GDMT use are evident with increased pharmacist involvement. Longer-term outcomes associated with this intervention warrant future investigation.
18
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Emelia J. Benjamin, Paul Muntner, Álvaro Alonso et al. · Circulation · 2019 · 9.1K citations · Full text
Spironolactone for Heart Failure with Preserved Ejection Fraction
Bertram Pitt, Marc A. Pfeffer, Susan F. Assmann et al. · New England Journal of Medicine · 2014 · 2.7K citations · Full text
Medicine, Cardiology, Pharmacology +16
2013 ACCF/AHA Guideline for the Management of Heart Failure
Clyde W. Yancy, Mariell Jessup, Biykem Bozkurt et al. · Circulation · 2013 · 2.1K citations
Bryan Williams, Thomas M. MacDonald, S. V. Morant et al. · The Lancet · 2015 · 1.2K citations · Full text
Pharmacy, Pharmacotherapy, Cardiovascular Pharmacotherapy +16